Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RXMD - Progressive Care Announces Record December and Full Year 2020 Performance Data
BY GlobeNewswire
— 7:00 AM ET 02/08/2021
MIAMI, FL, Feb. 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Progressive Care Inc. ( RXMD
Loading...
Loading...
) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is pleased to report performance data for the month of December and the full year of 2020, which featured robust growth in sales and prescriptions, as well as breakout growth in emerging income streams, including 340B administration fees and COVID-19 Rapid Testing services.
Full Year 2020 Performance Highlights
Consolidated gross sales across all locations for the twelve months ended December 31, 2020 totaled a Company record $40.6 million, representing year-over-year growth of 23% compared to the twelve months ended December 31, 2019.
Total prescriptions for the twelve months ended December 31, 2020 totaled 530,700, representing year-over-year growth of 16% compared to the twelve months ended December 31, 2019.
340B revenue was $2.8 million, representing year-over-year growth of 300% compared to the twelve months ended December 31, 2019.
Revenues from COVID-19 Rapid Testing totaled approximately $600,000 during 2020 with over 5000 tested.
December 2020 Performance Highlights
Consolidated gross sales for the month of December 2020 totaled $3.5 million, representing 9% year-over-year growth (compared to December 2019), and 3% sequential monthly growth (compared to November 2020).
Total prescriptions for the month of December 2020 totaled 46,200, representing 3% year-over-year growth (compared to December 2019), and 8.5% sequential monthly growth (compared to November 2020).
340B revenue was approximately $230,000 for the month of December 2020, representing 109% year-over-year growth (compared to December 2019).
Revenues from COVID-19 Rapid Testing totaled a record $345,000 for the month of December 2020, representing 115% sequential monthly growth (compared to November 2020).
In response to a challenging 2020 context, the Company was able to respond with flexibility and strong execution, capitalizing on Progressive Care’s built-in competitive advantages, including its established delivery infrastructure, to drive a seamless transition into a pandemic-ready operational vision. The Company’s strong results owe in part to its ability to shift in stride to a model centered on contactless prescription delivery, a range of digital solutions, and an overall experience for providers and customers that met the needs of its surrounding communities during an uncertain and unpredictable period.
The Company sees its December performance as particularly important given that it closed the year with one of its strongest months, suggesting both momentum and growing resilience.
Progressive Care ( RXMD
Loading...
Loading...
) stands ready to deliver the same strong service to its clients, patients, and providers in 2021 as the pandemic recedes and a more normalized operating environment reasserts itself, providing a further opportunity for the Company to serve its community as a continued strong force on the virus testing front as well as a key player in the effort to efficiently distribute critical vaccine resources.
Alan Jay Weisberg, CEO and Chairman of Progressive Care ( RXMD
Loading...
Loading...
), commented, “At some point, you’re going to face a test, and 2020 was a litmus test for many companies. We identified it as such at Progressive Care ( RXMD
Loading...
Loading...
) and worked proactively to innovate, and we emerged stronger than ever. It’s hard to find words to express how proud I am of our team, and we all look forward to a gradually normalizing operational environment in 2021.”
For more information about Progressive Care ( RXMD
Loading...
Loading...
), please visit the company’s website. Connect and stay in touch with us on social media:
Progressive Care Inc. ( RXMD
Loading...
Loading...
)
https://www.facebook.com/ProgressiveCareUS/
https://twitter.com/ProgressCareUS
PharmCoRx
https://www.pharmcorx.com/get-tested-now
https://www.facebook.com/pharmcorx/
https://twitter.com/PharmCoRx
ClearMetrX
$RXMD - UP 80% THIS WEEK! S-1 Registration filed November 9, 2020
$40 MILLION NET REVENUES in 2020
$RXMD - UP 80% THIS WEEK! S-1 Registration filed November 9, 2020
$40 MILLION NET REVENUES in 2020
I've been putting it on BB's and MOMO"s boards. I see some others have also. Maybe someone with a yahoo account or investorshub account can post there...
If we churn here for a few days I'm ok with that. Allows for more buys before the next leg up!
We jumped from 6's to 9's in less than 20 min with only 4 milly volume. That a HUGE buy signal!
$.10's today. $.12's tomorrow. However after $.10 we could just shoot past $.12.
Simple but Great Chart!
We should see 10's tomorrow at open. It flow to 9's today quick!
Word is finally getting out on this!
A few small ask slaps the end would be awesome!!!!
I think the buyers are mainly not here in IHUB. Something is coming for sure!
We are so close to 10,000,000 volume and $.10!!!
RXMD - I don't believe the buys are IHUB people, other entities are buying for sure!
Progressive Care Announces Record December and Full Year 2020 Performance Data
BY GlobeNewswire
— 7:00 AM ET 02/08/2021
MIAMI, FL, Feb. 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Progressive Care Inc. ( RXMD
Loading...
Loading...
) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is pleased to report performance data for the month of December and the full year of 2020, which featured robust growth in sales and prescriptions, as well as breakout growth in emerging income streams, including 340B administration fees and COVID-19 Rapid Testing services.
Full Year 2020 Performance Highlights
Consolidated gross sales across all locations for the twelve months ended December 31, 2020 totaled a Company record $40.6 million, representing year-over-year growth of 23% compared to the twelve months ended December 31, 2019.
Total prescriptions for the twelve months ended December 31, 2020 totaled 530,700, representing year-over-year growth of 16% compared to the twelve months ended December 31, 2019.
340B revenue was $2.8 million, representing year-over-year growth of 300% compared to the twelve months ended December 31, 2019.
Revenues from COVID-19 Rapid Testing totaled approximately $600,000 during 2020 with over 5000 tested.
December 2020 Performance Highlights
Consolidated gross sales for the month of December 2020 totaled $3.5 million, representing 9% year-over-year growth (compared to December 2019), and 3% sequential monthly growth (compared to November 2020).
Total prescriptions for the month of December 2020 totaled 46,200, representing 3% year-over-year growth (compared to December 2019), and 8.5% sequential monthly growth (compared to November 2020).
340B revenue was approximately $230,000 for the month of December 2020, representing 109% year-over-year growth (compared to December 2019).
Revenues from COVID-19 Rapid Testing totaled a record $345,000 for the month of December 2020, representing 115% sequential monthly growth (compared to November 2020).
In response to a challenging 2020 context, the Company was able to respond with flexibility and strong execution, capitalizing on Progressive Care’s built-in competitive advantages, including its established delivery infrastructure, to drive a seamless transition into a pandemic-ready operational vision. The Company’s strong results owe in part to its ability to shift in stride to a model centered on contactless prescription delivery, a range of digital solutions, and an overall experience for providers and customers that met the needs of its surrounding communities during an uncertain and unpredictable period.
The Company sees its December performance as particularly important given that it closed the year with one of its strongest months, suggesting both momentum and growing resilience.
Progressive Care ( RXMD
Loading...
Loading...
) stands ready to deliver the same strong service to its clients, patients, and providers in 2021 as the pandemic recedes and a more normalized operating environment reasserts itself, providing a further opportunity for the Company to serve its community as a continued strong force on the virus testing front as well as a key player in the effort to efficiently distribute critical vaccine resources.
Alan Jay Weisberg, CEO and Chairman of Progressive Care ( RXMD
Loading...
Loading...
), commented, “At some point, you’re going to face a test, and 2020 was a litmus test for many companies. We identified it as such at Progressive Care ( RXMD
Loading...
Loading...
) and worked proactively to innovate, and we emerged stronger than ever. It’s hard to find words to express how proud I am of our team, and we all look forward to a gradually normalizing operational environment in 2021.”
For more information about Progressive Care ( RXMD
Loading...
Loading...
), please visit the company’s website. Connect and stay in touch with us on social media:
Progressive Care Inc. ( RXMD
Loading...
Loading...
)
https://www.facebook.com/ProgressiveCareUS/
https://twitter.com/ProgressCareUS
PharmCoRx
$RXMD - UP 36%%% Progressive Care Announces Record December and Full Year 2020 Performance Data
BY GlobeNewswire
— 7:00 AM ET 02/08/2021
MIAMI, FL, Feb. 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Progressive Care Inc. ( RXMD
Loading...
Loading...
) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is pleased to report performance data for the month of December and the full year of 2020, which featured robust growth in sales and prescriptions, as well as breakout growth in emerging income streams, including 340B administration fees and COVID-19 Rapid Testing services.
Full Year 2020 Performance Highlights
Consolidated gross sales across all locations for the twelve months ended December 31, 2020 totaled a Company record $40.6 million, representing year-over-year growth of 23% compared to the twelve months ended December 31, 2019.
Total prescriptions for the twelve months ended December 31, 2020 totaled 530,700, representing year-over-year growth of 16% compared to the twelve months ended December 31, 2019.
340B revenue was $2.8 million, representing year-over-year growth of 300% compared to the twelve months ended December 31, 2019.
Revenues from COVID-19 Rapid Testing totaled approximately $600,000 during 2020 with over 5000 tested.
December 2020 Performance Highlights
Consolidated gross sales for the month of December 2020 totaled $3.5 million, representing 9% year-over-year growth (compared to December 2019), and 3% sequential monthly growth (compared to November 2020).
Total prescriptions for the month of December 2020 totaled 46,200, representing 3% year-over-year growth (compared to December 2019), and 8.5% sequential monthly growth (compared to November 2020).
340B revenue was approximately $230,000 for the month of December 2020, representing 109% year-over-year growth (compared to December 2019).
Revenues from COVID-19 Rapid Testing totaled a record $345,000 for the month of December 2020, representing 115% sequential monthly growth (compared to November 2020).
In response to a challenging 2020 context, the Company was able to respond with flexibility and strong execution, capitalizing on Progressive Care’s built-in competitive advantages, including its established delivery infrastructure, to drive a seamless transition into a pandemic-ready operational vision. The Company’s strong results owe in part to its ability to shift in stride to a model centered on contactless prescription delivery, a range of digital solutions, and an overall experience for providers and customers that met the needs of its surrounding communities during an uncertain and unpredictable period.
The Company sees its December performance as particularly important given that it closed the year with one of its strongest months, suggesting both momentum and growing resilience.
Progressive Care ( RXMD
Loading...
Loading...
) stands ready to deliver the same strong service to its clients, patients, and providers in 2021 as the pandemic recedes and a more normalized operating environment reasserts itself, providing a further opportunity for the Company to serve its community as a continued strong force on the virus testing front as well as a key player in the effort to efficiently distribute critical vaccine resources.
Alan Jay Weisberg, CEO and Chairman of Progressive Care ( RXMD
Loading...
Loading...
), commented, “At some point, you’re going to face a test, and 2020 was a litmus test for many companies. We identified it as such at Progressive Care ( RXMD
Loading...
Loading...
) and worked proactively to innovate, and we emerged stronger than ever. It’s hard to find words to express how proud I am of our team, and we all look forward to a gradually normalizing operational environment in 2021.”
For more information about Progressive Care ( RXMD
Loading...
Loading...
), please visit the company’s website. Connect and stay in touch with us on social media:
Progressive Care Inc. ( RXMD
Loading...
Loading...
)
https://www.facebook.com/ProgressiveCareUS/
https://twitter.com/ProgressCareUS
PharmCoRx
$RXMD - UP 36%%% Progressive Care Announces Record December and Full Year 2020 Performance Data
BY GlobeNewswire
— 7:00 AM ET 02/08/2021
MIAMI, FL, Feb. 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Progressive Care Inc. ( RXMD
Loading...
Loading...
) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is pleased to report performance data for the month of December and the full year of 2020, which featured robust growth in sales and prescriptions, as well as breakout growth in emerging income streams, including 340B administration fees and COVID-19 Rapid Testing services.
Full Year 2020 Performance Highlights
Consolidated gross sales across all locations for the twelve months ended December 31, 2020 totaled a Company record $40.6 million, representing year-over-year growth of 23% compared to the twelve months ended December 31, 2019.
Total prescriptions for the twelve months ended December 31, 2020 totaled 530,700, representing year-over-year growth of 16% compared to the twelve months ended December 31, 2019.
340B revenue was $2.8 million, representing year-over-year growth of 300% compared to the twelve months ended December 31, 2019.
Revenues from COVID-19 Rapid Testing totaled approximately $600,000 during 2020 with over 5000 tested.
December 2020 Performance Highlights
Consolidated gross sales for the month of December 2020 totaled $3.5 million, representing 9% year-over-year growth (compared to December 2019), and 3% sequential monthly growth (compared to November 2020).
Total prescriptions for the month of December 2020 totaled 46,200, representing 3% year-over-year growth (compared to December 2019), and 8.5% sequential monthly growth (compared to November 2020).
340B revenue was approximately $230,000 for the month of December 2020, representing 109% year-over-year growth (compared to December 2019).
Revenues from COVID-19 Rapid Testing totaled a record $345,000 for the month of December 2020, representing 115% sequential monthly growth (compared to November 2020).
In response to a challenging 2020 context, the Company was able to respond with flexibility and strong execution, capitalizing on Progressive Care’s built-in competitive advantages, including its established delivery infrastructure, to drive a seamless transition into a pandemic-ready operational vision. The Company’s strong results owe in part to its ability to shift in stride to a model centered on contactless prescription delivery, a range of digital solutions, and an overall experience for providers and customers that met the needs of its surrounding communities during an uncertain and unpredictable period.
The Company sees its December performance as particularly important given that it closed the year with one of its strongest months, suggesting both momentum and growing resilience.
Progressive Care ( RXMD
Loading...
Loading...
) stands ready to deliver the same strong service to its clients, patients, and providers in 2021 as the pandemic recedes and a more normalized operating environment reasserts itself, providing a further opportunity for the Company to serve its community as a continued strong force on the virus testing front as well as a key player in the effort to efficiently distribute critical vaccine resources.
Alan Jay Weisberg, CEO and Chairman of Progressive Care ( RXMD
Loading...
Loading...
), commented, “At some point, you’re going to face a test, and 2020 was a litmus test for many companies. We identified it as such at Progressive Care ( RXMD
Loading...
Loading...
) and worked proactively to innovate, and we emerged stronger than ever. It’s hard to find words to express how proud I am of our team, and we all look forward to a gradually normalizing operational environment in 2021.”
For more information about Progressive Care ( RXMD
Loading...
Loading...
), please visit the company’s website. Connect and stay in touch with us on social media:
Progressive Care Inc. ( RXMD
Loading...
Loading...
)
https://www.facebook.com/ProgressiveCareUS/
https://twitter.com/ProgressCareUS
PharmCoRx
This thing finally got it's legs! Building a solid new base!
THAT~LITTLE~TABLE~IS~VERY~ACCURATE
If we can hold 7's or 8's before January numbers are PR'd we are in great shape here!
Huge Bid Support!!!
Merger and News Coming! I'm holding on tight!
S-1 and Profits Coming!!!!
Hope you still held on to a lot of your shares! Patience was always key here!!!!
Almost 4 milly volume in first 30 min! Let's see 10+ milly and close above $.10!
It can churn here for a few days before it goes to $.05!
$RXMD - $40.6 MILLION REVENUES IN 2020! UP 36%%%%%%%%
$RXMD - $40.6 MILLION REVENUES IN 2020! UP 36%%%%%%%%
Wow that bid/ask just got real tight!
LOL! Finally people see the value here!
$RXMD - UP 36%%%%% RUNNING ON $40.6 MILLION REVENUES FOR 2020!!!!! HERE WE GO!!!!!!! from $.03 to $.09 this week alone!
9's up....soon 10's...not even half hour into trading!
$RXMD - UP 36%%%%% RUNNING ON $40.6 MILLION REVENUES FOR 2020!!!!! HERE WE GO!!!!!!!
$RXMD - UP 36%%%%% RUNNING ON $40.6 MILLION REVENUES FOR 2020!!!!! HERE WE GO!!!!!!!
$40.6 MILLION IN REVENUES HERE FOLKS IN 2020! THE REAL DEAL!
This has been years in the waiting! True valuation coming!
Bring on the 8's!!! Love the 2020 $40.6 MIL REV's!
New Buyers See The Value Here Now! Sorry for anyone selling down here!
We almost hit 7's....we shall see 7's today................
$.05! and higher....
RXMD~IS~AUDITED~$40~MIL~REVENUES~KINKY